Nighttime insomnia treatment and education for Alzheimer's disease: A randomized, controlled trial

被引:196
|
作者
McCurry, SM
Gibbons, LE
Logsdon, RG
Vitiello, MV
Teri, L
机构
[1] Univ Washington, Dept Psychosocial & Community Hlth, Seattle, WA 98115 USA
[2] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98115 USA
关键词
sleep; nocturnal disturbances; Alzheimer's disease; caregivers; actigraphy;
D O I
10.1111/j.1532-5415.2005.53252.x
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
OBJECTIVES: To evaluate whether a comprehensive sleep education program (Nighttime Insomnia Treatment and Education for Alzheimer's Disease (NITE-AD)) could improve sleep in dementia patients living at home with their family caregivers. DESIGN: A randomized, controlled trial. PARTICIPANTS: Thirty-six community-dwelling patients with Alzheimer's disease (AD) and their family caregivers. INTERVENTION: All participants received written materials describing age- and dementia-related changes in sleep and standard principles of good sleep hygiene. Caregivers in active treatment (n=17) received specific recommendations about setting up and implementing a sleep hygiene program for the dementia patient and training in behavior management skills. Patients in active treatment were also instructed to walk daily and increase daytime light exposure with the use of a light box. Control subjects (n=19) received general dementia education and caregiver support. MEASUREMENTS: Primary sleep outcomes were derived for patients and caregivers from 1 week of sleep-wake activity measured at baseline, posttest (2 months), and 6-month follow-up using an Actillume wrist-movement recorder. Secondary patient outcomes included the Epworth Sleepiness Scale, the Cornell Depression Scale, and the Revised Memory and Behavior Problem Checklist. Caregiver self-reports included the Pittsburgh Sleep Quality Index and the Center for Epidemiological Study of Depression Scale. RESULTS: Patients participating in NITE-AD showed significantly greater (P <.05) posttest reductions in number of nighttime awakenings, total time awake at night, and depression, and increases in weekly exercise days than control subjects. At 6-month follow-up, treatment gains were maintained, and additional significant improvements in duration of night awakenings emerged. When cognitive level was controlled, NITE-AD patients had lower longitudinal ratings of daytime sleepiness than controls. There was a trend for control subjects to spend more time in bed at 6 months than NITE-AD patients. CONCLUSION: This study provides the first evidence that patients with AD who are experiencing sleep problems can benefit from behavioral techniques (specifically, sleep hygiene education, daily walking, and increased light exposure) that are known to improve sleep in nondemented, institutionalized older adults.
引用
收藏
页码:793 / 802
页数:10
相关论文
共 50 条
  • [31] Randomized controlled trial of internet-based treatment of insomnia
    Andersson, G
    Strom, L
    Pettersson, R
    EUROPEAN PSYCHIATRY, 2002, 17 : 218S - 218S
  • [32] Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial
    Jia, Yujie
    Zhang, Xuezhu
    Yu, Jianchun
    Han, Jingxian
    Yu, Tao
    Shi, Jiangwei
    Zhao, Lan
    Nie, Kun
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2017, 17
  • [33] Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
    Yujie Jia
    Xuezhu Zhang
    Jianchun Yu
    Jingxian Han
    Tao Yu
    Jiangwei Shi
    Lan Zhao
    Kun Nie
    BMC Complementary and Alternative Medicine, 17
  • [34] Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial
    Scheltens, Philip
    Kamphuis, Patrick J. G. H.
    Verhey, Frans R. J.
    Rikker, Marcel G. M. Olde
    Wurtman, Richard J.
    Wilkinson, David
    Twisk, Jos W. R.
    Kurz, Alexander
    ALZHEIMERS & DEMENTIA, 2010, 6 (01) : 1 - 10
  • [35] Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease
    Herrmann, Nathan
    Ruthirakuhan, Myuri
    Gallagher, Damien
    Verhoeff, Nicolaas Paul L. G.
    Kiss, Alex
    Black, Sandra E.
    Lanctot, Krista L.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2019, 27 (11): : 1161 - 1173
  • [36] The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer’s disease: a randomized, triple-blind, placebo-controlled trial
    Luciana L. Louzada
    Flávio V. Machado
    Juliana L. Quintas
    Guilherme A. Ribeiro
    Mônica V. Silva
    Dayde L. Mendonça-Silva
    Bruno S. B. Gonçalves
    Otávio T. Nóbrega
    Einstein F. Camargos
    Neuropsychopharmacology, 2022, 47 : 570 - 579
  • [37] Caffeine for treatment of Parkinson's disease - A randomized controlled trial
    Postuma, R. B.
    Lang, A. E.
    Munhoz, R. P.
    Charland, K.
    Pelletier, A.
    Moscovich, M.
    Filla, L.
    Zanatta, D. R.
    Romenets, S. Rios
    Altman, R.
    Chuang, R.
    Shah, B.
    MOVEMENT DISORDERS, 2012, 27 : S135 - S135
  • [38] Obtaining personalized predictions from a randomized controlled trial on Alzheimer's disease
    Shen, Dennis
    Agarwal, Anish
    Misra, Vishal
    Schelter, Bjoern
    Shah, Devavrat
    Shiells, Helen
    Wischik, Claude
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [39] The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer's disease: a randomized, triple-blind, placebo-controlled trial
    Louzada, Luciana L.
    Machado, Flavio V.
    Quintas, Juliana L.
    Ribeiro, Guilherme A.
    Silva, Monica V.
    Mendonca-Silva, Dayde L.
    Goncalves, Bruno S. B.
    Nobrega, Otavio T.
    Camargos, Einstein F.
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 (02) : 570 - 579
  • [40] Patient Education for Patients with Parkinson's Disease - A Randomized Controlled Trial
    Magdalena, Chlond
    Felicitas, Bergmann
    Heike, Schnoor
    Karla, Eggert
    Astrid, Larisch
    ZEITSCHRIFT FUR PSYCHOSOMATISCHE MEDIZIN UND PSYCHOTHERAPIE, 2013, 59 (01): : 68 - 69